Liquidia Surges Nearly 37% After Settling United Therapeutics Litigation
Liquidia shares jumped nearly 37% in premarket trading after the drugmaker settled a years-long legal dispute with United Therapeutics over its lung disease drug. The settlement ends six lawsuits over patents, trade secrets and contracts.
Story updates
12:57:30 PM UTC
SquawkNews
By Mariapaula GonzalezThe legal dark cloud hanging over Liquidia stock has passed and analysts see a lot to like.The biotech reached a $380.7 million global settlement with United Therapeutics that resolved all six pending lawsuits between the companies to resolve all patent, trade secret, and anti…
Liquidia (NASDAQ:LQDA) shares rose nearly 37% in premarket trading on Wednesday after the drugmaker resolved a years-long legal dispute with United Therapeutics (NASDAQ:UTHR) concerning its lung disease drug. Announced late on Tuesday, the settlement ends six lawsuits involving patents, trade secrets and contracts.